Improving the lives of patients is our mission. We are an ambitious and dynamic business with a healthy innovation-driven pipeline that enables us to build on our core expertise in pain. Strong ongoing partnerships with leading healthcare and development organisations bring our new products to life. This commitment to innovation and thought-leadership means that next generation scientific talent is drawn to us.
Grünenthal. Change is possible.
We are present in 30 countries with affiliates in Europe, Latin America and the US.
Our products are sold in more than 100 countries.
4,900 employees work for our group worldwide.
Madrid, Spain, 12 June 2019 – A pan-European survey initiated by Grünenthal and presented at this year’s annual European Congress of Rheumatology (EULAR 2019) in Madrid indicates that gout is being diagnosed late and is not controlled effectively or monitored regularly enough. Despite these significant gaps in the management of the disease, 8 out of 10 patients claim they are satisfied with their current treatment1.
Aachen, Germany, 8 May 2019 – Grünenthal intends to realign its research and development activities. Today, the Corporate Executive Board informed the workforce about the background of the intended changes.
Brussels/Aachen, 2 May 2019 – The European Pain Federation EFIC® and the pharmaceutical company Grünenthal have announced the five research projects that will receive funding as part of the EFIC-Grünenthal Grant (E-G-G). With a total value of €200,000, this biennial grant supports young scientists in their quest to turn creative ideas into research projects that deliver life-changing pain management approaches.
Aachen, Germany, 22 January 2019– Grünenthal announced today that Fabian Raschke has been appointed Chief Financial Officer (CFO) and Member of the Corporate Executive Board. He will assume leadership of Grünenthal’s Finance and IT organisation on 1 February 2019. Fabian currently leads Grünenthal’s Group Controlling and manages over 150 employees, including Finance staff in the affiliates.
Aachen, Germany and Gothenburg, Sweden, 14 December 2018 – Grünenthal and OnDosis announced today that they have entered into an exclusive collaboration to develop the OnDosis’ technology for prescription medicines in all pain related indications. The agreement also entails an option for Grünenthal to an exclusive worldwide license to the technology in these indications. The handheld device enables individualised dosing of oral medicines in micro units, provides support for patient compliance, can be combined with digital solutions and thus significantly improves patients’ safety. The agreement with Grünenthal, a leading pain specialist, is the first partnering deal for life science startup OnDosis on their innovative technology. While this agreement covers the indication area pain; other focus areas of OnDosis, like ADHD and immunosuppression, remain available for further cooperation with third parties.